The epidemiology of medically attended respiratory syncytial virus in older adults in the United States: A systematic review
- PMID: 28797053
- PMCID: PMC5552193
- DOI: 10.1371/journal.pone.0182321
The epidemiology of medically attended respiratory syncytial virus in older adults in the United States: A systematic review
Abstract
Objective: This review was undertaken to assess the historical evidence of the disease incidence and burden of laboratory-confirmed respiratory syncytial virus (RSV) in medically attended older adults.
Design: A qualitative systematic literature review was performed; no statistical synthesis of the data was planned, in anticipation of expected heterogeneity across studies in this population.
Methods: A literature search of PubMed, Embase, and the Cochrane Library was conducted for studies of medically attended RSV in older adults (≥ 50 years) published in the last 15 years. Two independent reviewers screened titles and abstracts based on predefined inclusion and exclusion criteria.
Results: From 10 studies reporting incidence proportions, RSV may be the causative agent in up to 12% of medically attended acute respiratory illness in older adults unselected for comorbidities, with variations in clinical setting and by year. In multiple studies, medically attended-RSV incidence among older adults not selected for having underlying health conditions increased with increasing age. Of prospectively followed lung transplant recipients, 16% tested positive for RSV. In hospitalized adults with chronic cardiopulmonary diseases, 8% to 13% were infected with RSV during winter seasons (8%-13%) or metapneumovirus season (8%). Hospitalizations for RSV in older adults typically lasted 3 to 6 days, with substantial proportions requiring intensive care unit admission and mechanical ventilation. Among older adults hospitalized with RSV, the mortality rate was 6% to 8%.
Conclusions: Protection of older adults against RSV could reduce respiratory-related burden, especially as age increases and the prevalence of comorbidities (especially cardiopulmonary comorbidities) grows.
Conflict of interest statement
Figures
Similar articles
-
Impact of severe disease caused by respiratory syncytial virus in children living in developed countries.Pediatr Infect Dis J. 2003 Feb;22(2 Suppl):S13-8; discussion S18-20. doi: 10.1097/01.inf.0000053881.47279.d9. Pediatr Infect Dis J. 2003. PMID: 12671448
-
Epidemiology, clinical features, and resource utilization associated with respiratory syncytial virus in the community and hospital.Influenza Other Respir Viruses. 2020 May;14(3):247-256. doi: 10.1111/irv.12723. Epub 2020 Feb 20. Influenza Other Respir Viruses. 2020. PMID: 32077641 Free PMC article.
-
Incidence and economic burden of respiratory syncytial virus among adults in the United States: A retrospective analysis using 2 insurance claims databases.J Manag Care Spec Pharm. 2022 Jul;28(7):753-765. doi: 10.18553/jmcp.2022.21459. Epub 2022 May 3. J Manag Care Spec Pharm. 2022. PMID: 35503888
-
The burden of Respiratory Syncytial Virus (RSV) infection in the Middle East and North Africa (MENA) region across age groups: A systematic review.Vaccine. 2021 Jun 29;39(29):3803-3813. doi: 10.1016/j.vaccine.2021.05.076. Epub 2021 Jun 4. Vaccine. 2021. PMID: 34099329 Review.
-
Economic burden of respiratory syncytial virus infection in adults: a systematic literature review.J Med Econ. 2023 Jan-Dec;26(1):742-759. doi: 10.1080/13696998.2023.2213125. J Med Econ. 2023. PMID: 37167068 Review.
Cited by
-
Vaccine Prevention of Respiratory Syncytial Virus Infection in Older Adults: The Work Continues.J Infect Dis. 2017 Dec 12;216(11):1334-1336. doi: 10.1093/infdis/jix504. J Infect Dis. 2017. PMID: 29029125 Free PMC article. No abstract available.
-
RSV vaccination in older adults: Addressing vaccine hesitancy using the 3C model.Can Pharm J (Ott). 2023 Nov 24;157(1):39-44. doi: 10.1177/17151635231210879. eCollection 2024 Jan-Feb. Can Pharm J (Ott). 2023. PMID: 38125630 Free PMC article.
-
The HRA2pl fusion peptide exerts in vitro antiviral activity against human respiratory paramyxoviruses and pneumoviruses.Front Cell Infect Microbiol. 2023 Apr 20;13:1125135. doi: 10.3389/fcimb.2023.1125135. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37153148 Free PMC article.
-
Respiratory Syncytial Virus (RSV) Hospitalizations in the Elderly in a Tertiary Care Hospital in Southern Italy as a Useful Proxy for Targeting Vaccine Preventive Strategies.Infect Dis Rep. 2024 May 31;16(3):491-498. doi: 10.3390/idr16030037. Infect Dis Rep. 2024. PMID: 38920893 Free PMC article.
-
Increase in Detection of Respiratory Syncytial Virus Among Older Adults in Arizona : An Association With Changes in Testing Practices.Public Health Rep. 2021 Jul-Aug;136(4):421-427. doi: 10.1177/0033354920976353. Epub 2021 Feb 4. Public Health Rep. 2021. PMID: 33541204 Free PMC article.
References
-
- Hall CB, Simoes EA, Anderson LJ. Clinical and epidemiologic features of respiratory syncytial virus. Curr Top Microbiol Immunol. 2013; 372: 39–57. doi: 10.1007/978-3-642-38919-1_2 - DOI - PubMed
-
- Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010; 375 (9725): 1545–1555. doi: 10.1016/S0140-6736(10)60206-1 - DOI - PMC - PubMed
-
- Branche AR, Falsey AR. Respiratory syncytial virus infection in older adults: an under-recognized problem. Drugs Aging. 2015; 32 (4): 261–269. doi: 10.1007/s40266-015-0258-9 - DOI - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical